Nordion Provides Update on Europe-Focused Phase III Clinical Trial for TheraSphere® Yttrium-90 Liver Cancer Treatment

Published: Sep 06, 2012

OTTAWA, Ontario--(BUSINESS WIRE)--Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, today provided an update on its YES-P clinical trial for TheraSphere®, the company’s Yttrium-90 (Y-90) glass microsphere liver cancer treatment, by naming the principal investigators (PI) and contract research organization (CRO) for the study.

Back to news